A study of nearly 800 pediatric AML patients has uncovered a striking finding: racial survival disparities are not driven by differences in relapse rates. Black, white, and Hispanic children all relapsed at similar rates — yet Black and Hispanic children had significantly worse 5-year overall survival compared to white patients, suggesting the gap lies elsewhere in the care continuum.

The culprit, at least in part, appears to be how sick children are when they first arrive at diagnosis. Black children were more than twice as likely to present with high cardiovascular acuity and three times as likely to show high renal acuity compared to white children. These factors mediated a meaningful portion of the survival gap, pointing to delayed diagnoses, unequal access to care, insurance disparities, and even environmental exposures as potential contributors.

Key Takeaways:

• 5-year OS: white children 70% vs. Black children 61.1% vs. Hispanic children 65.4%
• Black children had 2.09x higher cardiovascular acuity and 3.08x higher renal acuity at presentation vs. white children
• Cardiovascular acuity mediated up to 14% of OS differences between Black and white children; respiratory acuity mediated up to 8%
• Relapse rates did not significantly differ by race or ethnicity

Why it matters: These findings reframe where interventions need to happen — not just at the cancer center, but upstream, before a child ever walks through the door. Addressing access to care, implicit bias, and environmental inequities may be just as critical as advances in AML treatment itself.